Answers are grounded in this paper and cite their sources.
A phase 3 trial of rituximab vs ocrelizumab in newly diagnosed relapsing-remitting MS gave a remarkably diplomatic result.Rituximab was non-inferior to ocrelizumab in suppressing MRI disease activity between 6 and 24 months.Relapse, disability and cognitive outcomes were similar, although analyses were underpowered to exclude clinically important differences.The separation came with infection rates: 82% with rituximab vs 69% with ocrelizumab.Most were mild, but with no long-term safety data.However, rituximab's lower acquisition cost looks different when including recurrent infections.Patients might end up paying the difference in coughs and antibiotics.
No takes yet. Share an insight, caveat, or question.
A Fo Ben (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: